Mydecine Innovations Group Inc MYDECINE INNOVATIONS GROUP FILES PROSPECTUS SUPPLEMENT, ANNOUNCES CLOSING UNDER SHARE SUBSCRIPTION AGREEMENTS
31 October 2023 - 6:00PM
UK Regulatory
TIDMMYIG
[image]
MYDECINE INNOVATIONS GROUP FILES PROSPECTUS SUPPLEMENT, ANNOUNCES CLOSING UNDER
SHARE SUBSCRIPTION AGREEMENTS
VANCOUVER, BC, 31 October 2023 - Mydecine Innovations Group Inc. ("Mydecine" or
the "Company") (CSE:MYCO) (AQSE:MYIG) (OTC:MYCOF) (FSE:0NFA) a biotechnology
company engineering the next wave of innovative medications and treatment
protocols to directly address mental health with a particular emphasis on
addiction and PTSD, is pleased to announce that, in connection with: (i) its
previously announced Common Share Subscription Agreement (the "Opensky
Subscription Agreement") with OpenSky Opportunities Fund Ltd. ("Opensky") dated
10 March 2023; and (ii) a Common Share Subscription Agreement dated 25 October
2023 (the "Standalone Subscription Agreement", and collectively with the Opensky
Subscription Agreement, the "Subscription Agreements") between the Company and
an arms-length investor (the "Standalone Investor" and collectively with
Opensky, the "Investors"), the Company has filed a shelf prospectus supplement
(the "Prospectus Supplement") to the Company's Final Short Form Base Shelf
Prospectus for the province of Québec and Amended and Restated Final Short Form
Base Shelf Prospectus for each of the provinces of Canada, dated 28 January 2022
(together, the "Shelf Prospectus").
The Prospectus Supplement provides, among other things, that the Company is
qualifying the distribution of up to 7,360,000 common shares (each a "Share") in
the capital of the Company to the Investors under the Subscription Agreements at
a price of $0.15 per Share for aggregate gross proceeds of up to $1,104,000.
The Company also announces today the closing of Share issuances under the
Subscription Agreements (the "Offerings"). The Offerings resulted in the
issuance of 7,360,000 Shares at a price of $0.15 per Share for aggregate gross
proceeds of $1,104,000. The distribution of such Shares is qualified by the
Prospectus Supplement. The Company will use the proceeds of the Offering as
described in the Prospectus Supplement.
An application will be made to the Aquis Stock Exchange ("Aquis") for the
7,360,000 new Shares to be admitted to trading. Admission is expected to take
place, and dealings on Aquis in the Shares are expected to commence, at 08:00 on
or around 3 November 2023.
Following Admission, the Company will have 52,567,458 Ordinary Shares in issue.
Since the Company currently holds no shares in treasury, the total number of
voting rights in the Company will therefore be 52,567,458. These figures may
therefore be used by Shareholders as the denominator for the calculations by
which they will determine if they are required to notify their interest in, or a
change in their interest in, the share capital of the Company under the FCA's
Disclosure Guidance and Transparency Rules.
The Prospectus Supplement and Base Shelf Prospectus are available on the Company
website and on the Company's profile on the System for Electronic Document
Analysis and Retrieval (SEDAR+) at www.sedarplus.ca.
About Mydecine Innovations Group
Mydecine Innovations Group is a publicly traded, pre-revenue biopharmaceutical
company that began operations in North America and Europe in early 2020.
Mydecine was founded to increase physicians' access to serotonin-modulating
medicine. Recent research has demonstrated the therapeutic potential of
psychedelic substances such as psilocybin and MDMA for treating intractable
conditions such as pain, anxiety, depression, addiction, and PTSD, along with
neurodegenerative disorders. Mydecine believes these compounds can be safer,
more effective, and more accessible for patients and medical professionals
through modern drug chemistry paired with artificial intelligence (AI). Through
its exclusive partnership with Applied Pharmaceutical Innovation based at the
University of Alberta, Mydecine is developing innovative medications for target
indications with high mortality rates that have lacked innovation for decades
and are controlled by dominant corporations. Mydecine developed several prodrug
families, beginning with a psilocybin-derived smoking cessation drug undergoing
a NIDA-funded trial at Johns Hopkins University. Mydecine is also developing
MYCO-006-short-acting chemical analogs derived from MDMA for treating various
conditions, including anxiety and pain. Mydecine utilises cutting-edge
artificial intelligence (AI) and pharma research infrastructure at the
University of Alberta to develop and manufacture new medications to make them
affordable and accessible to the general public upon Health Canada and FDA
approval. The Mydecine team is enthusiastic about its mission and is dedicated
to creating a positive difference in the lives of others.
The Directors of Mydecine take responsibility for this announcement.
This announcement contains inside information for the purposes of Article 7 of
the Market Abuse Regulation (EU) 596/2014 as it forms part of UK domestic law by
virtue of the European Union (Withdrawal) Act 2018 ("MAR"), and is disclosed in
accordance with the Company's obligations under Article 17 of MAR.
Learn more at: https://www.mydecine.com/ and follow the company on Twitter,
LinkedIn, YouTube, and Instagram.
For more information, please contact:
Media Contact
pr@mydecineinc.com
Investor Relations
investorrelations@mydecineinc.com
On behalf of the Board of Directors
Joshua Bartch, Chief Executive Officer contact@mydecineinc.com
AQSE Corporate Advisor
Novum Securities LimitedTel: +44 (0)207 399 9400
David Coffman/ George Duxberry
For further information about Mydecine, please visit the Company's profile on
SEDAR at https://sedar.com/ or visit the Company's website at
https://www.mydecine.com/.
Forward-Looking Statements
Certain statements in this news release constitute "forward-looking information"
within the meaning of applicable Canadian securities legislation. Forward
-looking statements and information are provided for the purpose of providing
information about management's expectations and plans relating to the future.
All of the forward-looking information made in this news release is qualified by
the cautionary statements below and those made in our other filings with the
securities regulators in Canada. Forward-looking information contained in
forward-looking statements can be identified by the use of words such as "are
expected," "is forecast," "is targeted," "approximately," "plans,"
"anticipates," "projects," "anticipates," "continue," "estimate," "believe" or
variations of such words and phrases or statements that certain actions, events
or results "may," "could," "would," "might," or "will" be taken, occur or be
achieved. All statements, other than statements of historical fact, may be
considered to be or include forward-looking information. This news release
contains forward-looking information regarding, the use of proceeds and the
closing of the Offering. Readers are cautioned that these forward-looking
statements are neither promises nor guarantees, and are subject to risks and
uncertainties that may cause future results to differ materially from those
expected. Although the Company has attempted to identify important factors that
could cause actual results to differ materially from those contained in forward
-looking information, there may be other factors that cause results not to be as
anticipated, estimated or intended. There can be no assurance that such
information will prove to be accurate, as actual results and future events could
differ materially from those anticipated in such information.
The forward-looking information set forth herein reflects the Company's
reasonable expectations as at the date of this news release and is subject to
change after such date. The Company disclaims any intention or obligation to
update or revise any forward-looking information, whether as a result of new
information, future events or otherwise, other than as required by law. The
forward-looking information contained in this news release is expressly
qualified by this cautionary statement.
This news release shall not constitute an offer to sell or the solicitation of
an offer to buy nor shall there be any sale of the securities in any State in
which such offer, solicitation or sale would be unlawful. The securities being
offered have not been, nor will they be, registered under the United States
Securities Act of 1933, as amended, and may not be offered or sold in the United
States absent registration or an applicable exemption from the registration
requirements of the United States Securities Act of 1933, as amended, and
applicable state securities laws.
2
MYDECINE INNOVATIONS GROUP INC.
Suite 810-789 West Pender Street, Vancouver, British Columbia, V6C 1H2 T: 604
-687-2038
This information was brought to you by Cision http://news.cision.com
https://news.cision.com/mydecine-innovations-group-inc/r/mydecine-innovations-group-files-prospectus-supplement--announces-closing-under-share-subscription-a,c3866091
The following files are available for download:
https://news.cision.com/mydecine-innovations-group-inc/i/3866091-0-jpeg,c3233950 3866091_0.jpeg
END
(END) Dow Jones Newswires
October 31, 2023 03:00 ET (07:00 GMT)
Mydecine Innovations (AQSE:MYIG)
Historical Stock Chart
From Aug 2024 to Sep 2024
Mydecine Innovations (AQSE:MYIG)
Historical Stock Chart
From Sep 2023 to Sep 2024